Zydus Cadila gets approval for muscle spasticity drug

Zydus Cadila, a part of Cadila Healthcare, has informed the bourses that it has received final approval from USFDA for its abbreviated new drug application (ANDA).

The company has received final approval from USFDA to market Baclofen tablets, 5 mg.

Baclofen is used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury/disease. It works by helping to relax the muscles. It will be manufactured at the group’s formulations manufacturing facility at Baddi (Himachal Pradesh).

The group now has 288 approvals and has so far, filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila's FY19 revenue mix comprised of US formulations (50 per cent), India formulations (29 per cent), EMB formulations (six per cent), animal health (four per cent), wellness (four per cent), API (three per cent), alliances (two per cent) and Europe formulations (two per cent).

Today, the stock of Cadila Healthcare gained nearly two per cent and made an intraday high of Rs 341 on BSE.